Thomas Desautels | 20-ERD-032
By integrating computational and experimental tools (including high-throughput, in vitro assays), we will develop a platform for the rapid design of antibodies and vaccine antigens. Based on machine learning, this revolutionary platform will enable a scalable, rapid response to biothreats.
Publications, Presentations, and Patents
Arrildt, K., et al. 2020. "Using Antibody-Antigen Interactions to Design Better Vaccine Antigens." Antibodies as Drugs: From B Cell Biology to New Treatments, Santa Fe, NM, February 2020. LLNL-POST-803860
Auten, H. H., et al. 2020. "3D Protein Models Shed Light on Coronavirus." LLNL-WEB-805168
Zemla, A. T. 2020. "Estimated Antibody Complexes for Novel Coronavirus (2019-nCoV) Spike Protein." doi:10.1101/2020.04.03.024885v1.supplementary-material. LLNL-MI-803855